What is the history of drug discovery?

 Drug Discovery in modern times straddles three main periods. The first notable period can be traced to the nineteenth century where the basis of drug discovery relied on the serendipity of the medicinal chemists. The second period commenced around the early twentieth century when new drug structures were found, which contributed for a new era of antibiotics discovery. 

Based on these known structures, and with the development of powerful new techniques such as molecular modelling, combinatorial chemistry, and automated high-throughput screening, rapid advances occurred in drug discovery towards the end of the century.

To know more about drug discovery  JOIN WITH US AT drug discovery 2023 which is going to be held at 

Paris, France

For more details : Drug discovery 2023


Comments

Post a Comment

Popular posts from this blog

What is meant by drug development?

Image
    Drug development is a term used to define the entire process of bringing a new drug or device to market. It is an integrated, multidisciplinary endeavor that includes drug discovery, chemistry and pharmacology, nonclinical safety testing, manufacturing, clinical trials, and regulatory submissions. This report summarizes presentations of a workshop entitled "Drug Development 101," held at the 39th Annual Meeting of the American College of Toxicology in West Palm Beach, Florida. The workshop was designed to provide an introductory overview of drug development. Experienced scientists from industry and government provided overviews of each area, with a focus on safety assessment, and described some of the challenges that can arise. The role of chemistry and manufacturing was discussed in the context of early- and late-stage product development and approaches to assess, control, and limit impurities. The toxicologic assessment was emphasized in early-phase development, from th
Read more

Why is drug discovery important?

Image
  The goal of a preclinical drug discovery program is to deliver one or more clinical candidate molecules, each of which has sufficient evidence of biologic activity at a target relevant to a disease as well as sufficient safety and drug-like properties so that it can be entered into human testing. Most discovery programs seek to produce more than one candidate molecule because, as is shown in, many molecules do not move through the entire process because of problems with safety, kinetics, potency, intellectual property protection, or other factors. There is no simple formula for producing a viable clinical candidate molecule, although extensive collaboration of chemistry, biology, toxicology, and pharmacokinetics is almost universally the norm in modern drug discovery programs small molecule drug discovery programs typically produce massive amounts of data using high-throughput screening techniques that evaluate many compounds at many doses against many assays For more deatails :  Dru
Read more

What is Rule of 3 drug discovery?

Image
  The value of using the RO3 in FBDD is being (correctly) challenged4 as many useful fragment hits do not adhere to its restrictions (see the Practical Fragments blog website). We have always believed that the RO3 concept has limitations and, like other rules related to desirable physicochemical properties, such as the 'rule of five' guidelines5, it is simply a guideline that should not be overemphasized. Nevertheless, we believe that the RO3 has been useful in ensuring that fragment libraries really do consist of compounds with fragment-like properties, although reports of 'fragment' hits that actually resemble lead-like compounds — particularly considering their substantial molecular mass — do still appear. The fundamental concept of fragment screening is to use simpler molecules so that the chemical space can be sampled much more efficiently than is possible when using molecules of greater complexity6. One consequence of screening smaller, simpler fragments is that t
Read more